Mankind Pharma Ltd. 6 announced its financial results for the first quarter of FY27, delivering robust top-line and bottom-line expansion driven by steady chronic therapy demand, consumer brand strength, and operational efficiency.
The company reported Q1 FY27 total revenues of ₹4,031 crore, marking a 12.9% year-on-year (YoY) increase. Domestic revenues (excluding consumer healthcare) grew 11.0% YoY to reach ₹3,180 crore. Operational performance was highlighted by a significant 24.7% YoY increase in EBITDA, which rose to ₹1,060 crore, reflecting disciplined execution and margin expansion.
Growth during the quarter was primarily anchored by the expanding chronic therapy portfolio, with continued outperformance across Cardiac and Anti-Diabetes segments. Concurrently, Mankind’s flagship consumer healthcare brandssuch as Manforce, Prega News, and Gas-O-Fast further solidified their market positions. The continued momentum within the acquired Bharat Serums and Vaccines (BSV) business also contributed positively to the company’s diversified product pipeline.
“Our strong start to FY27 demonstrates the resilience and strategic depth of our healthcare ecosystem,” the company noted in a statement. “We remain focused on advancing our core purpose of making quality healthcare accessible and affordable while driving sustainable, long-term value creation.”
Written by: Pragna Biswas
Graphics by: Pramit Hazra
